Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M.

Mol Cancer Ther. 2019 Jul 10. pii: molcanther.0207.2019. doi: 10.1158/1535-7163.MCT-19-0207. [Epub ahead of print]

PMID:
31292166
2.

Metabolic signature of extracellular vesicles depends on the cell culture conditions.

Palviainen M, Saari H, Kärkkäinen O, Pekkinen J, Auriola S, Yliperttula M, Puhka M, Hanhineva K, Siljander PR.

J Extracell Vesicles. 2019 Apr 4;8(1):1596669. doi: 10.1080/20013078.2019.1596669. eCollection 2019.

3.

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H.

BMC Cancer. 2018 May 2;18(1):504. doi: 10.1186/s12885-018-4418-2.

4.

Efficient ultrafiltration-based protocol to deplete extracellular vesicles from fetal bovine serum.

Kornilov R, Puhka M, Mannerström B, Hiidenmaa H, Peltoniemi H, Siljander P, Seppänen-Kaijansinkko R, Kaur S.

J Extracell Vesicles. 2018 Jan 21;7(1):1422674. doi: 10.1080/20013078.2017.1422674. eCollection 2018.

5.

Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.

Puhka M, Takatalo M, Nordberg ME, Valkonen S, Nandania J, Aatonen M, Yliperttula M, Laitinen S, Velagapudi V, Mirtti T, Kallioniemi O, Rannikko A, Siljander PR, Af Hällström TM.

Theranostics. 2017 Aug 23;7(16):3824-3841. doi: 10.7150/thno.19890. eCollection 2017.

6.

KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine.

Puhka M, Nordberg ME, Valkonen S, Rannikko A, Kallioniemi O, Siljander P, Af Hällström TM.

Eur J Pharm Sci. 2017 Feb 15;98:30-39. doi: 10.1016/j.ejps.2016.10.021. Epub 2016 Oct 19.

PMID:
27771514
7.

Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

af Hällström TM, Puhka M, Kallioniemi O.

EMBO Mol Med. 2015 Aug;7(8):994-5. doi: 10.15252/emmm.201505332.

8.

ER sheet persistence is coupled to myosin 1c-regulated dynamic actin filament arrays.

Joensuu M, Belevich I, Rämö O, Nevzorov I, Vihinen H, Puhka M, Witkos TM, Lowe M, Vartiainen MK, Jokitalo E.

Mol Biol Cell. 2014 Apr;25(7):1111-26. doi: 10.1091/mbc.E13-12-0712. Epub 2014 Feb 12.

9.

Progressive sheet-to-tubule transformation is a general mechanism for endoplasmic reticulum partitioning in dividing mammalian cells.

Puhka M, Joensuu M, Vihinen H, Belevich I, Jokitalo E.

Mol Biol Cell. 2012 Jul;23(13):2424-32. doi: 10.1091/mbc.E10-12-0950. Epub 2012 May 9.

10.
11.

Characterization and subcellular localization of human neutral class II alpha-mannosidase [corrected].

Kuokkanen E, Smith W, Mäkinen M, Tuominen H, Puhka M, Jokitalo E, Duvet S, Berg T, Heikinheimo P.

Glycobiology. 2007 Oct;17(10):1084-93. Epub 2007 Aug 6. Erratum in: Glycobiology. 2008 Feb;18(2):136.

PMID:
17681998
12.

p37 is a p97 adaptor required for Golgi and ER biogenesis in interphase and at the end of mitosis.

Uchiyama K, Totsukawa G, Puhka M, Kaneko Y, Jokitalo E, Dreveny I, Beuron F, Zhang X, Freemont P, Kondo H.

Dev Cell. 2006 Dec;11(6):803-16.

Supplemental Content

Support Center